Background
==========

Cervical carcinoma stands as the first cause of death among the Mexican female population with 14 deaths per 100,000 women with 15 years old or more, representing 34.2 % of all new female cancer cases reported \[[@B1]\]. High risk human papillomavirus (HPV) infection is considered to be the most important risk factor associated with the development of this tumor, and is present in 99.7% of the invasive cervical tumors worldwide \[[@B2]\].

Comparative Genomic Hybridization (CGH) is a method employed in cancer genomics that allows the detection of DNA gains or losses at the genome level in a single hybridization experiment, indicating cytogenetic regions that might be involved in the transformation process. CGH has detected a specific pattern of chromosomal imbalances associated with particular stages of cervical transformation, and with different biological behaviors \[[@B3]-[@B10]\]. In this paper, we evaluated the presence of HPV DNA and analyzed the pattern of chromosomal imbalances using CGH in four cell lines established from tumor explants of Mexican patients. The establishment and research use of two of these cell lines has been previously reported \[[@B11],[@B12]\]. Further genomic characterization of these lines will open new possibilities for understanding cervical carcinoma, since the coincidence between the chromosomal imbalances present in these cell lines and patterns found in cervical tumors indicate that they are good models for the study of cervical cancer.

Methods
=======

The cell lines were established from stages IIA and IVA squamous cell cervical carcinoma explants from Mexican females (Table [1](#T1){ref-type="table"}) at the National University of Mexico, as previously described \[[@B11],[@B12]\]. Cell lines were designated CALO, INBL, VIPA and ROVA.

###### 

Chromosomal imbalances detected in hpv18 positive cell lines

  ***Cell line***   ***Tumor stage***   ***DNA Losses***                                                                                                                                                                                                                                   ***DNA Gains***                                                                                                                                                                                                                                                                                              ***Total***
  ----------------- ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------
  *CALO*            *II-B*              *1pter-p32, 2q35-qter, 4pter-p15.2, 4q32-qter, 5q33-qter, 6q24-qter, 8pter-p22, 8q24.2-qter, 9q32-qter, 11q12, 12p13, 12q22-qter, 13q12, 15q11.2-q12, 16p, 16q22-qter, 17, 18q11, 19, 20, 21, 22. Total:21*                                        *1p31-p12, 1q22-q31, 2p15, 2q21-q32, 3p22, 3q11.2-q26.3, 4q26-q31.2, 5p, 5q11.2-q23, 6q22, 7p15-p12, 7q21-q31, 9p23-p21, 11q14-q22, 12p11.2, 12q15-q21, 13q21-q31, 18q12. Total: 18*                                                                                                                         *39*
  *VIPA*            *II-A*              *1p32-pter, 2p24, 2q35-qter, 4p15.3-pter, 4q33-qter, 5q33-qter, 6q25-qter, 7p22, 7q33 qter, 8p21-pter, 9q32-qter, 10p13-pter, 10q24-qter, 11q12, 12p13, 12q22-qter, 14q31-qter, 16p, 16q13-qter, 17, 18q22, 19, 20p13, 20q, 21q22, 22. Total:26*   *1p12-p22, 1q23-q32, 2q21-q32.3, 3p22, 3p13-p12, 3q13.1-q13.3, 3q22-q25, 4q13, 4q22-q31.3, 5p, 5q11.2-q12, 5q14-q23, 6p12-p21.1, 6q12-q16, 7p12-p21, 7q21-q31, 8q21.1-q22, 9p21-p22, 10q21, 11p13, 11q14-q22, 12p11.2, 12q14-q21, 13q 14-q31, 14q12-q13, 15q21. Total: 26*                                   *52*
  *INBL*            *IV-A*              *2q34-qter, 4p, 4q32-qter, 6q24-qter, 8p22, 13q12, 18p21-pter, 19p13.2-pter. Total: 8*                                                                                                                                                             *1q12-q41, 3q12-q26.3, 5p, 6p24-p22, 6p21.1-p11.1, 7p14-p11.1, 7q21-q31, 11p15, 11q21, 12q12, 15q22-q24. Total: 11*                                                                                                                                                                                          *19*
  *ROVA*            *IV-A*              *1p35-pter, 2p25, 2q35-qter, 3q29-qter, 4p16, 5q35, 6q26-qter, 7p22, 8p23, 8q24.1-qter, 9q33-qter, 10q26, 12p13, 12q24.1-qter, 16p, 16q22-qter, 17p12-pter, 17q23-qter, 18q22-qter, 19, 20q13.1-qter, 21q22, 22q. Total: 23*                       *1p12-p31, 1q22-q32, 2p11.2-p16, 2q21-q33, 3p12-p22, 3q13.1-q26.3, 4p12-p15.2, 4q12-q31.3, 5p12-p15.1, 5q11.2-q31, 6p22-p23, 6p12-p, 6q12-q15, 6q22, 7p12-p15, 7q21-q31, 8p22, 8q13, 9p21-p23, 9q21, 11p14, 11q14-q24, 12p12, 12q12-q21, 13q14-q31, 14q11.2-q24, 15q15-q21, 15q24, 18q11.2-q12. Total: 28*   *51*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                    *Average*           *19.5*                                                                                                                                                                                                                                             *20.7*                                                                                                                                                                                                                                                                                                       *ANCA:40.2*

All tumors were diagnosed as squamous cell carcinomas. ANCA: Average Number of Chromosomal Aberrations, obtained dividing the total number of observed alterations between the total number of cases.

HPV detection was done using the L1 consensus primers MY09/MY11. After denaturation at 94°C for 5 minutes, 100 ng of DNA were subjected to 40 cycles of 94°C for 1 min, 55°C for 2 min and 73°C for 3 min, with a final extension step of 7 min at 72°C. The amplicon was labeled using the Big Dye kit (Applied Biosystems, Foster City, CA) and sequenced with an ABI 373 automated sequencer. BLAST sequence comparison was done in order to know the HPV type.

All CGH procedures were performed using reagents and kits from Vysis Inc. (Downers Grove, IL), following the manufacturer\'s instructions. Cell line DNA was labeled using the CGH nick translation kit, and the hybridization mixture was prepared according to the CGH reagent kit, consisting of 200 ng of spectrum-green labeled cell line DNA, 100 ng of spectrum-red labeled normal male reference DNA and 20 μg of human Cot-1 DNA. Hybridization was performed over 3 days at 37°C on normal male metaphase spreads (Vysis, Downers Grove, IL).

Digital images were collected using the Smart Capture (Vysis) software with a charged coupled device camera mounted on an epifluorescence microscope. An average of 15 metaphases per case were analysed using the Vysis CGH software using a \>1.2 ratio threshold for detecting DNA gains and \<0.8 for losses, these thresholds were chosen based on previous normal VS. normal hybridizations. Sex chromosomes and heterochromatic areas (centromeric and paracentromeric regions of chromosomes 1, 9, 16, p arms of acrocentric chromosomes) were excluded from the analysis. A \"reverse painting\" experiment was used as a control for the CGH results. CGH data from the cell lines is available at the NCI and NCBI Spectral Karyotyping (SKI) and CGH Database <http://www.ncbi.nlm.nih.gov/sky/skyweb.cgi>.

Results and Discussion
======================

HPV DNA was detected in all the cell lines. Sequence analysis identified HPV18 in all the samples. All the cell lines presented chromosomal imbalances. A line summary ideogram of the chromosomal imbalances in the cell lines is presented in Figure [1](#F1){ref-type="fig"}. A complete description of the imbalances detected in each cell line is presented in Table [1](#T1){ref-type="table"}. On the average, 19.5 DNA losses and 20.7 gains were detected in the samples, with an average number of chromosomal aberrations of 40.2 alterations per case, ranging from 52 alterations in VIPA to 19 alterations in INBL. The most prevalent imbalances were gains in chromosomes 1q23-q32, 3q11.2-q13.1, 3q22-q26.1, 5p15.1-p11.2. This alteration is present as a high copy number amplification in three of the cell lines, 7p15-p13, 7q21, 7q31, 11q21, and 12q12, and losses in 2q35-qter, 4p16, 6q26-qter, 9q34 and 19q13.2-qter. Comparison between chromosomal imbalances in these cell lines and those found in cervical tumors; indicate the presence of common genetic alterations, suggesting that they represent their tissue of origin. These common regions include gains in 3q22-q26.2 and 5p, and losses on 2q35-qter, 4q32-qter and 18q. Some of these alterations have been detected in early stages of cervical transformation and are conserved in advanced tumors or have been associated with the presence of metastases and with a worse clinical behavior \[[@B6],[@B7],[@B10]\], making the cells good models for the study of genes involved in the maintenance of the transformed phenotype. Compared with the imbalances previously found on HPV18 positive cases \[[@B9]\], there is coincidence for the DNA gains at 1q31-q32, 3q22-q26.3, 5p14 and 7p13-p14, as well as in DNA losses at 2q33-qter and 6q26-q27. Differences among the cell lines and data from invasive cervical tumors were also found. For example, we did not find deletions of 3p or 11q regions in the cell lines. This situation might be explained by the enrichment or selection of a particular cell clone during the cell line establishment.

![CGH ideograms of the genetic imbalances detected in the cell lines. The lines at the right of the chromosome ideogram represent DNA gains, lines at the left, DNA losses. Thick lines represent high copy number amplifications or multi copy deletions (ratio \>1.4 or \<0.6). The mark closest to the ideogram represents the cell lines CALO, followed by VIPA, INBL and ROVA.](1471-2407-3-8-1){#F1}

A common observation in uterine cervix carcinomas is the integration of HPV DNA into the cellular genome. However, the consequences of this integration event are only poorly understood. Differences in the frequency of HPV18 and HPV16 integration have been detected, 72% of the HPV16 tumors presented viral integration, while HPV18 positive tumors had viral integration in 100% of the cases \[[@B13],[@B14]\]. This is a possible explanation for the observed HPV18 incidence in the studied cell lines, since the integration event might represent a growth advantage for the cell in culture. Analysis of our present findings and previously reported data suggest that gains at 1q31-q32 and 7p13-p14, as well as losses at 6q26-q27 are alterations that are unique for HPV18 positive cases. HPV integration at the 1q31-q32 has been found in nasal epithelial cells immortalized with HPV16 DNA and also contains the short tandem repeat region F13B \[[@B15]\]. The NEK7 (NIMA (never in mitosis gene a)-related kinase 7, 1q31.3) gene is located in this region and plays an important role in the control of mitosis initiation \[[@B16]\]. The role of this gene in human cancer has not been explored. Regarding the 7p15-p13 region, a lymphocyte fragile site has been detected at 7p13, high copy number amplification of this region was also found by us in primary cervical carcinomas \[[@B9]\] and gain of 7p was also found in HPV transfected cells during the immortalization process \[[@B4]\]. The PE5L gene, (7p13-p14) presents a sequence homology with the HPV18 E5 gene, making this gene a possible target for recombination and viral integration \[[@B17]\]. However, alignment of the PE5L sequence against the November 2002 freeze of the Human Genome working draft, showed the best matching score on 7p11.2 (not shown). The public availability of viral-cellular fusion transcripts or DNA sequences, combined with data from the human genome, will certainly help to better define areas of viral integration for further investigation.

The lost cytogenetic region 6q26 comprises the fragile site FRA6E, the third most frequently observed common fragile site. Deletion of the 6q26-q27 region has been found in approximately 44% of all tumor types analyzed by CGH \[[@B18]\], and in cervical carcinoma loss of heterozigosity was found 39% of the cases \[[@B19]\]. An interesting gene located in this region is the mitogen-activated protein kinase kinase kinase 4 (MAP3K4), a major mediator of environmental stresses that activate the CSBP2 MAPK pathway, which, in turn, regulates the expression of TNF and several cytokines, and controls the initiation of the G2/M checkpoint after UV radiation \[[@B20]\].

We also found high copy number amplifications in regions 7q21, 7q31, 11q21 and 11q12. Region 7q21 contains the rare, folic acid type FRA7E fragile site and a cellular-HPV fusion transcript has been detected at this area, with no sequence match to a known gene \[[@B21]\]. 7q31 has been reported to be the site of a chromosomal breakpoint in cervical carcinoma cell lines \[[@B22]\] and contains the c-Met oncogene, whose over-expression has been correlated to the diameter of the primary tumor, deep cervical stromal invasion, presence of metastatic lymph node and number of metastatic lymph nodes \[[@B23]\]. The 11q21-q22 region was also found in our cell lines, this region has been found amplified in some cervical carcinoma cell lines and over-expression of the cIAP1 gene, an apoptosis inhibitor and possible target of the amplification, was related to a poorer overall survival and local recurrence-free survival in cervical carcinoma \[[@B24]\].

It is interesting to notice that almost all of the possible HPV18 related sites of chromosomal imbalance, as well as the regions with high copy number amplifications in our cell lines correspond to the location of fragile sites in the human genome. Since HPV integration preferentially seems to target these kind of fragile sites, it is possible that HPV18 is integrated into these altered chromosomal regions in our cell lines. Recently, a comprehensive characterization of cervical cancer cell lines gave very useful information about specific chromosomal alterations, DNA gains, losses and clusters of chromosome breakpoints in cervical cancer cell lines and their relation to HPV presence and integration \[[@B24]\]. Currently, such a characterization of our newly established cell lines is being carried out.

Conclusions
===========

High throughput genetic analysis often require vast amounts of tissue that sometimes is not available, making the cell lines the model of choice to overcome this problem. Here, we report the presence of HPV18 and the pattern of chromosomal imbalances detected in four newly established uterine cervix carcinoma derived cell lines. The pattern of genetic imbalances in these cell lines suggest that they represent good models for cervical carcinoma and HPV18 infection, providing another useful cellular model for the discovery and functional analysis of genomic alterations involved in cervical cancer when this viral type is present.
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